Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 54Nivolumab 50Ipilimumab 28Cyclophosphamide 16binimetinib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10fludarabine 9Radiosurgery 9relatlimab 8encorafenib 8Opdualag 8Biopsy 8aldesleukin 7Interleukin-2 7atezolizumab 6Immunotherapy 6Blood Specimen Collection 6cemiplimab 5CTLA-4 Antigen 5Bevacizumab 5trametinib 4fludarabine phosphate 4dabrafenib 4Temozolomide 4Paclitaxel 4Immune Checkpoint Inhibitors 4spartalizumab 3Surgical Procedures, Operative 3Metformin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Melanoma × Lidocaine, Prilocaine Drug Combination × Clear all
NCT06223659 2026-03-10

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
100 enrolled
Dermatologic

Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡